|
AU2015316719A1
|
|
Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as S100-inhibitors
|
|
KR20170083121A
|
|
Quinoline carboxamides for use in the treatment of leukemia
|
|
KR20170052691A
|
|
Quinoline carboxamides for use in the treatment of multiple myeloma
|
|
EP2991990A1
|
|
Novel compounds useful as s100-inhibitors
|
|
KR20160006717A
|
|
N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors
|
|
US2013123301A1
|
|
Crystalline salts of quinoline compounds and methods for preparing them
|
|
EA021171B1
|
|
Method for manufacturing of quinoline-3-carboxamides
|
|
EP2537517A1
|
|
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
|
|
EP2316818A1
|
|
Method for the preparation of 2-amino-6-ethylbenzoic acid
|
|
EP2150819A1
|
|
S100a9 interaction screening method
|
|
GB0801084D0
|
|
Screening method
|
|
EP1986009A1
|
|
Screening method
|
|
ZA200701182B
|
|
Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
|
|
CN1980937A
|
|
Thienopyridone carboxamides and their medical use
|
|
AP200603674A0
|
|
New composition containing quinoline compounds.
|
|
BRPI0507390A
|
|
compound and pharmaceutical composition
|
|
EP1711175A1
|
|
Diurea derivatives
|
|
CN1917873A
|
|
Diurea derivatives
|
|
ZA200605585B
|
|
Diurea derivatives
|
|
AU2004316218A1
|
|
Novel benzofurans and indols
|
